Clinical study of Eloctate/Elocta yields positive results for Biogen and SOBI

10 August 2015

New clinical data shows that patients taking extended-interval prophylaxis regimens with Eloctate/Elocta (Antihemophilic Factor (Recombinant), Fc Fusion Protein) from Biogen (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) experienced low bleeding rates.

The interim results of this Phase III, open-label extension study, ASPIRE, were published in the online edition of the journal for the World Federation of Hemophilia,the European Association for Hemophilia and Allied Disorders, and the Hemostasis & Thrombosis Research Society.

Study participants completing the Phase III A-LONG and Kids A-LONG studies could participate in ASPIRE. The majority of participants in ASPIRE maintained or extended their dosing intervals between treatments, compared to the A-LONG and Kids A-LONG studies. According to the interim analysis, the median time in the ASPIRE study was 80.9 weeks for adults and adolescents completing A-LONG, and 23.9 for children completing Kids A-LONG.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK